Get the Stockscreener App
8.26
0.60%
-0.05
Pre-market:
8.26
Amneal Pharmaceuticals Inc stock is traded at $8.26, with a volume of 1.08M.
It is down -0.60% in the last 24 hours and up +2.35% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$8.31
Open:
$8.35
24h Volume:
1.08M
Relative Volume:
1.03
Market Cap:
$2.56B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-12.14
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+3.64%
1M Performance:
+2.35%
6M Performance:
+11.17%
1Y Performance:
+57.63%
1-Day Range:
$8.165
$8.38
1-Week Range:
$7.69
$8.42
52-Week Range:
$5.01
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
8.26 | 2.56B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Assenagon Asset Management S.A. Decreases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
Hennessy Advisors Inc. Acquires 106,600 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Is Targeting 70% Of Untapped Biologics In The ‘Golden Era’ Of Biosimilars - Citeline News & Insights
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year? - MSN
FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Driven by Rising Allergy Prevalence; AI Driving Market TransformationTechnavio - The Malaysian Reserve
Amneal expects to meet or top annual guidance - MSN
Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2024 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals Maintains Transparency with SEC Filing - TipRanks
JPMorgan Chase & Co. Grows Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Insider Sell: Gautam Patel Sells 62,590 Shares of Amneal Pharmac - GuruFocus.com
Amneal Pharmaceuticals director Patel sells $501,345 in stock By Investing.com - Investing.com Canada
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 62,590 Shares - MarketBeat
The 3.1% return this week takes Amneal Pharmaceuticals' (NASDAQ:AMRX) shareholders three-year gains to 74% - Simply Wall St
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Testosterone Replacement Therapy Market to Grow by USD 461 Million (2025-2029), Driven by Awareness Initiatives on Hypogonadism and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Amneal (AMRX) Upgraded to Strong Buy: Here's Why - MSN
Amneal Sues Sandoz to Block Copies of New Parkinson's Drug (1) - Bloomberg Law
Amneal Calls Teva's IP Delisting Panic 'Theatrical Distraction' - Law360
Amneal Pharmaceuticals director Gautam Patel sells $139,454 in stock By Investing.com - Investing.com Nigeria
Insider Selling: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Sells 17,410 Shares of Stock - MarketBeat
Amneal Pharmaceuticals director Gautam Patel sells $139,454 in stock - Investing.com India
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices - Benzinga
Here’s Why Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
Jane Street Group LLC Has $681,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Decrease in Short Interest - MarketBeat
Geode Capital Management LLC Purchases 378,136 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Barclays PLC Buys 169,756 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:AMRX) - MarketBeat
Epinephrine Autoinjector Market Growth, Trends & Forecast - openPR
State Street Corp Boosts Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
82,596 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Acquired by Wellington Management Group LLP - MarketBeat
Teva loses US appeal to keep inhaler patents on FDA protected drug list - Reuters
Amneal Pharmaceuticals (NASDAQ:AMRX) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 4.5%Here's What Happened - MarketBeat
Teva Makes Two Inhalers Free For Charity Amid Ongoing Patent Battle With Amneal - News & Insights
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Average Price Target from Analysts - MarketBeat
BNP Paribas Financial Markets Sells 402,852 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growth - Investing.com Australia
Parkinson's Disease Market to Reach New Heights in Growth - openPR
SERD Therapeutics Market Key Players AnalysisAmneal - openPR
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Driven by Rising Allergy Prevalence and AI-Powered Market TransformationTechnavio - The Malaysian Reserve
Jacobs Levy Equity Management Inc. Sells 189,881 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Charles Schwab Investment Management Inc. Buys 202,863 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):